Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

February 8, 2017

Uneven Distribution of Drugs in Mesothelioma Tissue May Explain Lack of Treatment Responses

News

The cancer drug Taxol (paclitaxel) is very unevenly distributed in a model of malignant pleural mesothelioma, according to a new imaging technique that visualizes how a drug spreads within a ... Read more

January 31, 2017

Various Mesothelin-targeting Treatments for Mesothelioma Are in Clinical Trials

News

Several antibodies that bind to mesothelin, intended for the treatment of malignant mesothelioma and other cancers, are in various stages of development. Because the antibody-based drugs have different properties, clinical ... Read more

January 27, 2017

New Mesothelin-targeting Combo Shows Promise Against Cancer Cells in Mice Studies

News

An antibody and drug combination by Bayer that targets the molecule mesothelin was found to have potent anti-cancer effects on lab-grown cells and animal models of malignant mesothelioma, according to a ... Read more

January 25, 2017

Therapy Restricting Growth of Blood Vessels Failed in Mesothelioma Clinical Trial

News

An investigational cancer drug that restricts the growth of new blood vessels failed to improve disease in a Phase 2 clinical trial in patients with malignant pleural mesothelioma who progressed after ... Read more

January 23, 2017

Mayo Clinic Expert Stands By Checkpoint Immunotherapy’s Potential for Treating Pleural Mesothelioma

News

Many scientists may have lost their initial high hopes for checkpoint immunities in treating malignant pleural mesothelioma (MPM), but Aaron S. Mansfield, MD, at the Mayo Clinic remains convinced immunotherapy will ... Read more

January 16, 2017January 16, 2017

Asbestos-Triggered Cell Change May Be Start of Mesothelioma Development

News

Asbestos triggers a change in cells that makes them take on fibrosis-promoting properties. That change — which could be the first step in the development of malignant mesothelioma — takes ... Read more

January 12, 2017

Electron Microscopy of Cells in Lung Liquid Can Aid Mesothelioma Diagnosis

News

Transmission electron microscopy — a high-resolution method to explore cell characteristics — can aid in the diagnosis of malignant pleural mesothelioma when examining cells found in the liquid surrounding the ... Read more

December 16, 2016December 20, 2016

Combo Treatment, Including Lung-Sparing Surgery, Helps Mesothelioma Patients Live Years Longer

News

A combination of lung-sparing surgery, chemotherapy, and using light to kill malignant cells helped patients with malignant pleural mesothelioma live years longer than those who received chemotherapy only, according to ... Read more

December 8, 2016December 8, 2016

Positive Results in Phase 2 Mesothelioma Trial of Nintedanib Supports Phase 3 Study

News

Boehringer Ingelheim’s Phase 2 clinical trial investigating nintedanib in malignant pleural mesothelioma showed improvements in both progression-free and overall survival compared to treatment with chemotherapy alone. The company is now recruiting patients for ... Read more

December 6, 2016December 6, 2016

Liver Enzyme Levels and White Blood Cell Counts May Predict Outcomes in Mesothelioma

News

In a study exploring the predictive power of several laboratory findings in malignant pleural mesothelioma, researchers found that high levels of a liver enzyme called aspartate aminotransferase (AST), and increased numbers ... Read more